Highest-materiality recent filing
Ashland Q1 sales down 5% to $386M; narrows FY2026 EBITDA guidance to $400–420M
Net loss of $12M (($0.26)/diluted share); Adjusted EPS excl. intangibles amortization $0.26.
Ashland permanently appoints William Whitaker as CFO; base salary $414,600
William Whitaker permanently appointed SVP, CFO effective July 18, 2025; previously interim CFO since May 6.
Ashland Q1 sales $405M (-14% YoY), net loss $165M; reiterates FY2025 outlook
Sales $405M, down 14% YoY; portfolio optimization cut 11% (excluding optimization, sales down 3%).
Ashland Q4 sales $522M (+1% YoY), adj. EBITDA $124M (+68%), issues FY2025 outlook
Sales $522M, up 1% YoY; nutraceuticals divestiture and CMC/MC curtailments reduced sales ~$24M (5%).
Ashland Q3 adjusted EBITDA up 5% to $139M; adjusted EPS $1.49 beats prior year $1.23
Sales $544M flat YoY; adjusted EBITDA $139M (+5%) on volume gains, favorable mix, and deflationary raw materials.
Ashland to sell nutraceuticals business to Turnspire; expects $110-120M impairment in Q3 FY2024
Signed definitive agreement to sell nutraceuticals business to Turnspire Capital Partners; closing expected calendar Q3 2024.
Sales $575M, down 5% YoY; net income $120M ($2.39 diluted), up from $91M.
Ashland Q1 sales down 10% YoY to $473M; adj. EBITDA falls 35% to $70M
Net income from continuing ops $28M ($0.54 diluted EPS) vs $42M ($0.76) a year ago; adjusted EPS excl. intangibles $0.45 vs $0.97.
Ashland posts preliminary Q4 net loss of $4M; Adj. EBITDA $74M, below expectations
Preliminary Q4 sales $518M; full-year sales $2.19B. Net loss $4M in Q4, net income $178M in FY.
Ashland sees Q3 sales down ~15%, EBITDA down 22-25%; cuts FY23 outlook; announces $1B buyback
Preliminary Q3 sales expected $545-550M (down ~15% YoY); adjusted EBITDA $130-135M (down 22-25%).
Ashland raises quarterly dividend 15% to $0.385, announces $100M share repurchase plan
Quarterly dividend increased 15% to $0.385 per share, payable June 15, 2023 to holders of record June 1, 2023.
Ashland Q1 sales $525M (+3% YoY), adj. EPS $0.97, EBITDA $108M, reaffirms FY guidance
Net income $40M ($0.73 diluted), income from continuing ops $42M ($0.76 diluted).
Prelim Q1 adjusted EPS $0.97; adjusted EBITDA $108M (+2% YoY, +15% constant-currency).
On May 15, 2026, the Board of Directors (the “Board”) of Ashland Inc. (the “Company”) increased the size of the Board from eight to nine directors and appointed Mr. Bertrand Loy to serve as an independent director on the Board, effective the same day.
On May 1, 2025, J. Kevin Willis notified Ashland Inc. (the “Company”) of his intention to resign as the Company’s Senior Vice President, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective May 16, 2025 (the “Effective Date”), to pursue another opportunity.
On May 5, 2025, the Company’s Board of Directors (the “Board”) appointed William C. Whitaker, the Company’s Vice President, Finance and Director, Investor Relations, to serve as the Company’s Interim Chief Financial Officer, effective May 6, 2025.
On May 5, 2025, the Board also appointed Samuel A. Richardson, the Company’s Controller, to serve as Vice President, Controller and Principal Accounting Officer of the Company, effective May 6, 2025.
On January 21, 2025, the Board of Directors of Ashland Inc. (“Ashland” or the “Company”) appointed J. Kevin Willis, the Company’s Senior Vice President, Chief Financial Officer and Principal Financial Officer, to also serve as the Company’s Principal Accounting Officer, effective January 21, 2025.
On November 19, 2024, Ashland Inc (the “Company”) and Eric F. Boni, the Company’s Vice President, Finance and Principal Accounting Officer, agreed that Mr. Boni will depart from the Company following a brief transition period.
On October 30, 2024, Wetteny Joseph, a member of the Board of Directors (the “Board”) of Ashland Inc. (the “Company”), notified the Company of his decision to not stand for reelection to the Board at the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”).
On May 6, 2024, the Board of Directors (“Board”) of Ashland Inc. (“Company”) elected Ashish K. Kulkarni, to the Board to serve as an independent director, and also appointed him to serve as a member of the Board's Environmental, Health, Safety, and Quality Committee and the Compensation Committee, in each case effective May 6, 2024.
On April 29, 2024, Ashok Kalyana submitted his resignation from his role as Senior Vice President, and General Manager, Life Sciences and Intermediates of Ashland Inc. effective May 10, 2024.
On April 10, 2024, the Board of Directors (“Board”) of Ashland Inc. (“Company”) elected Scott A. Tozier to the Board to serve as an independent director, and also appointed him to serve as a member of the Board's Audit Committee and the Environmental, Health, Safety, and Quality Committee, in each case effective April 15, 2024.
On February 20, 2024, Ashland Inc. (the “Company”) and Min Chong, the Company’s Senior Vice President and General Manager, Personal Care and Specialty Additives, agreed that Mr. Chong will depart from the Company on April 30, 2024.
On November 13, 2023, the Board of Directors (“Board”) of Ashland Inc. (“Company”) elected Sanat Chattopadhyay to the Board to serve as an independent director
Max materiality 0.80 · Median 0.40 · Most common event earnings